Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file a motion with the Court by April 13, 2026 [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate targeting Huntington's Disease, including the lack of full FDA approval [5]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5]. - As a result of these misrepresentations, the lawsuit asserts that the statements made by uniQure regarding its business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in terms of settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

uniQure N.V. (NASDAQ:QURE) anticipates a quarterly loss of $0.93 per share with projected revenue of $4.7 million.The company is involved in a class action lawsuit for alleged securities law violations, potentially impacting its financial performance.Financial metrics reveal a negative P/E ratio of -4.26 and a high price-to-sales ratio of 66.94, indicating financial challenges.uniQure N.V. (NASDAQ:QURE), a biotechnology company known for its focus on gene therapy, is set to release its quarterly earnings on ...

Group 1 - The article discusses the importance of staying updated on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The Haggerston BioHealth group provides insights on catalysts, buy and sell ratings, product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

SAN DIEGO, Feb. 26, 2026 /PRNewswire/ --Â Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure N.V. is based in Amsterdam and focuses on developing and commercializing gene therapies for severe diseases, particularly Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250%, from $13.66 to $47.50 per share, following positive statements [3]. - On November 3, 2025, it was revealed that the FDA agreement on study design was not finalized, causing a stock price drop of over 49%, from $67.69 to $34.29 per share [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the approval status of its Pivotal Study by the FDA [5] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5] - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements regarding its business and operations during the specified class period from September 24, 2025, to October 31, 2025 [2][3] Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased uniQure ordinary shares during the class period [2] - Investors have until April 13, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2] Group 2: Allegations - The complaint alleges that uniQure's management made materially false statements and failed to disclose adverse facts about the company's business [3] - Specific allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline [3] - As a result, the statements made by the defendants regarding the company's business and prospects lacked a reasonable basis [3] Group 3: Next Steps for Investors - Investors who purchased uniQure shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4] - The law firm offers a no-cost consultation for affected investors [4]

Core Viewpoint - The article discusses a class action lawsuit against uniQure N.V. related to alleged securities fraud, with a deadline for investors to seek lead plaintiff status by April 13, 2026 [1]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased uniQure securities between September 24, 2025, and October 31, 2025 [1]. - Allegations include that the design of uniQure's Pivotal Study was not fully approved by the FDA and that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to additional studies [1]. Company Disclosure - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from Phase I/II studies of AMT-130 would be adequate for BLA submission, leading to uncertainty regarding the BLA submission timeline [1]. - Following this disclosure, uniQure's share price fell by $33.40, approximately 49.33%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1].